Loading stock…

Janux Therapeutics, Inc. (JANX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Janux Therapeutics, Inc.

JANXMarket cap $1.10BPrice $17.9

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops T-cell engager therapies designed to attack tumors while sparing healthy tissue, using a "binder masking" technology that stays inactive until it reaches cancer cells. It's a precision approach big pharma keeps betting on—Merck and Amgen are already Janux's partners.

In Bastion Portfolios?

52W Return-33%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+5%5

Revenue Forecast

Rev CAGR (1y)+85%10

Rev CAGR (3y)-23%1

Rev CAGR (5y)+69%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-598%1

Net Income Margin-427%1

Free Cash Flow Margin-175%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-11%1

ROA-10%1

Earnings Stabilityna–

GEAR+VERY WEAK3

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV1.29

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-3.8%2

Dividend Yieldna–

Momentum

Short term

1 month return-11%2

3 month return+8%8

YTD return+30%8

Mid term

Price vs 52wHigh51%1

1 year return-26%2

Long term

3 year return+78%7

5 year return-16%3

Risk Shield

Price Risk

Beta1.13

Volatility92%1

Free Cash Flow

Free Cash Flow Margin-175%1

Free Cash Flow Yield-3.8%2

Quality

ROCE-15%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

JANXJanux Therapeutics

Revenue FY25$10M

GROWTH RATING↗

AVERAGE44 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+85%10

Revenue, next 3Y, CAGR-23%1

Revenue, next 5Y, CAGR+69%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to shrink 23%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 69%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 44% of companies worldwide.

WEAKNESSES

Revenue grew 5%/yr over the last 3 years, but it is set to shrink 23%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return+8%8

YTD return+30%8

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-26%2

3-year return+78%7

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+8%) and so far this year (+30%).

WATCH

Average long-term results. Multi-year returns are middling (+78% over three years and -16% over five), roughly average for the market.

WEAKNESSES

It's down 26% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-11%).

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Janux Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

JANXJanux Therapeutics

Revenue FY25$10M

GROWTH RATING↗

AVERAGE44 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+85%10

Revenue, next 3Y, CAGR-23%1

Revenue, next 5Y, CAGR+69%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to shrink 23%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 69%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 44% of companies worldwide.

WEAKNESSES

Revenue grew 5%/yr over the last 3 years, but it is set to shrink 23%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return+8%8

YTD return+30%8

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-26%2

3-year return+78%7

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+8%) and so far this year (+30%).

WATCH

Average long-term results. Multi-year returns are middling (+78% over three years and -16% over five), roughly average for the market.

WEAKNESSES

It's down 26% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-11%).

BOTTOM LINE

Fresh Momentum

04Value

Are you paying a fair price for it?

Stop guessing on Janux Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community